韩悦
教授,主任医师,博士生导师
苏州市工业园区仁爱路199号
www.优德88.cpm 造血干细胞移植研究所
E-mail:hanyuesz@163.com
教育背景:
1999/09-2002/07www.优德88.cpm/江苏省血液研究所 血液学专业 博士
1996/09-1999/07www.优德88.cpm/江苏省血液研究所 血液学专业 硕士
1987/09-1992/07南京医科大学 临床医学专业 学士
工作经历:
2012/07-至今 www.优德88.cpm 附属第一医院血液科 教授,主任医师
2013/08-2014/02美国oklahoma大学,血管生理系,合作导师:Lijun Xia夏利军
2009/05-2009/11美国UPENN大学,血液学,合作导师:Long Zheng郑兴龙
2006/07-2012/07www.优德88.cpm 附属第一医院血液科 副教授,副主任医师
2001/10-2002/10法国Bordeaux大学,血液学专业,合作导师:Alan Nurden
研究方向:
1.移植相关性血栓性微血管病变发病机制与治疗的研究
2.造血干细胞移植后难治性血小板减少的研究
3.恶性血液病与血小板的相关研究
代表性论文:(*通讯作者,#共同一作)
1. Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D,Han Y*. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.Front Immunol. 2021 Jan20; 11:564647.
2. Qi J, Zhang R, Cai C, Wang H, Zhou M, Shen W, Tang Y, Pan T, Wu D,Han Y*. HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.Ann Hematol. 2021 Apr 12.
3. Tang Y, Chen J, Liu Q, Chu T, Pan T, Liang J, He XF, Chen F, Yang T, Ma X, Wu X, Hu S, Cao X, Hu X, Hu J, Liu Y, Qi J, Shen Y, Ruan C,Han Y*, Wu D*. Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial.Blood Adv. 2021 Mar9;5(5):1250-1258.
4. Zhou M, Qi J, Li X, Zhang Z, Yao Y, Wu D,Han Y*. The proportion of patients with thrombocytopenia in three human-susceptible coronavirus infections: a systematic review and meta-analysis.Br J Haematol. 2020 May;189(3):438-441.
5. Lv X, Qi J, Zhou M, Shi B, Cai C, Tang Y, Pan T,Han Y*. Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis.Crit Rev Oncol Hematol. 2020 Jun; 150:102944.
6. Li X, Zhou M, Qi J,Han Y*. Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.Clin Lymphoma Myeloma Leuk. 2020 Dec 17:S2152-2650(20):31014-4.
7. Miao W, Song B, Shi B, Wan Q, Lv Q, Chen H, Zhu M, Zhang L,Han Y*, Wu D. Immune Thrombocytopenia Plasma-Derived Exosomes Impaired Megakaryocyteand Platelet Production through an Apoptosis Pathway.Thromb Haemost. 2020 Oct29.
8. Chen C, Qi JQ, Chu TT, Wang H, Wu DP, Ruan CG,Han Y*. Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Treatment of Intermediate Risk Acute Myeloid Leukemia with Negative for FLT3-ITD.NPM1 or Biallelic CEBPA Mutation. 2020 Jun;28(3):731-736.
9. Yang M, Qi J, Tang Y, Wu D,Han Y*. Increased D-dimer predicts therisk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: A systematic review and meta-analysis.Thromb Res. 2020 Dec;196:410-413. 10. Zhang Z, Zhang R, Qi J, Miao W, Fang K, Ruan C, Wu D,Han Y*. The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis.Leuk Lymphoma. 2020 Nov;61(11):2682-2691.
11. Chu T, Wang H, Lv X, Qi J, Tang Y, Fan Y, Qiu H, Tang X, Fu C, Ruan C,Han Y*, Wu DP. Investigation of fibrinogen in early bleeding of patients with newly diagnosed acute promyelocytic leukemia.Platelets. 2020 Aug 16:1-7.
12. Wang H, Li XQ, Chu TT, Han SY, Qi JQ, Tang YQ, Qiu HY, Fu CC, Tang XW, Ruan CG, Wu DP,Han Y*. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual diseasein cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.J Cancer Res Clin Oncol. 2021 Feb 7.
13.Yue Han, Yaqiong Tang, Jia Chen, Jianying Liang, Chunmei Ye, Changgeng Ruan, Depei Wu. Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study.JAMA Oncol. 2015;1(2):249-252.
14. Pan T, Qi J, Liu Y,Wu D,Han Y*. Comments on the article 'Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.Br J Haematol.2019;184(5):881-882.
15. Pan T, Qi J, You T, Han S, Yang L, Miao W, Wu D, Ruan C, Zhu L,Han Y*. Circulating HemeOxygenase-1 and Complement Activation in Transplant-Associated Thrombotic Microangiopathy.Biol Blood Marrow Transplant. 2019;25(8):1486-1491.
16. Wang H, Zhang T, QiJ, Chu T, Miao M, Qiu H, Fu C, Tang X, Ruan C, Wu D,Han Y*. Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation inmyelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation.Ann Hematol. 2019;98(4):987-996.
17. Wang H, Chu T, Han S, Qi J, Tang Y, Qiu H, Fu C, Tang X, Ruan C, Wu D,Han Y*. FLT3-ITD and CEBPA mutations predict prognosis in acute myeloid leukemia irrespective of hematopoietic stem cell transplantation.Biology of Blood and Marrow Transplantation. 2019;25(5):941-948.
18. Yaqiong Tang, Miao Miao, Shiyu Han, Jiaqian Qi, Hong Wang, Changgeng Ruan, Depei Wu,Yue Han*. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.Crit Rev Oncol Hematol. 2019;133:74-83.
19. Yang L, Qi J, Pan T, You T, Ruan C,Han Y*. Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Semin Thromb Hemost. 2019;45 (8), 767-777.
20. Qi J,You T, Li J, Pan T, Xiang L,Han Y*, Zhu L. Circulating Trimethylamine N-Oxide and the Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis of 11 Prospective Cohort Studies.J Cell Mol Med. 2018;22(1):185-194.
21. Pan T, Qi J, You T, Yang L, Wu D,Han Y*, Zhu L,Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.Leukemia Research. 2018;71:13-24.
22. Jiaqian Qi, Tao You, Tingting Pan, Qi Wang, Li Zhu,Yue Han*. Downregulation of hypoxia-inducible factor-1α contributes to impaired megakaryopoiesis in immune thrombocytopenia.Thrombosis and Haemostasis. 2017,117(10): 1875-1886.
23. Wang H, Zhang T, Jin S, Liu H, Zhang X, Ruan C, Wu D,Han Y*, and Wang X. Pyrosequencing Quantified Methylation Level of Mir-124 Predicts Shorter Survival for Patients with Myelodysplastic Syndrome.Clin Epigenetics. 2017;30(9):91-100.
24. Hong Wang, Man Huang, Ying Zhao, Jia-Qian Qi, Chun Chen, Ya-qiong Tang, Hui-ying Qiu, Cheng-Cheng Fu, Xiao-Wen Tang, De-pei Wu, Chang-geng Ruan,Yue Han*. Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation,Biol Blood Marrow Transplant. 2017 ;23(10):1678-1684.
25. Xiao-Qin Wang; Hong Wang; Tong-Tong Zhang; Song Jin; Hong Liu; Xiang Zhang; De-Pei Wu; Chang-Geng Ruan;Yue Han*. Pyrosequencing quantified methylation level of miR-124predicts shorter survival for patients with myelodysplastic syndrome.Clinical Epigenetics. 2017; 30(9);91-100.
26. Jiaqian Qi, Jie Wang, Jia Chen, Jian Su, Yaqiong Tang, Xiaojin Wu, Xiao Ma, Feng Chen, Changgeng Ruan, X. Long Zheng, Depei Wu,Yue Han*. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased inpatients with thrombotic microangiopathy after allogeneic stem cell transplantation.Annals of Hematology. 2017;96(11);1849-1855.
27. Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, Wu D,Han Y*. Impact of JAK2V617FMutation Burden on Disease Phenotype in Chinese Patients withJAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia(ET).Int J Med Sci. 2016, 25;13(1):85-91.
28. Tang Y, Wu Q, Wu X, Qiu H, Sun A, Ruan C, Wu D,Han Y*. Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia.Pak J MedSci. 2015;31(6):1389-1393.
29. Zhu Q, Wang H, Ruan J, Guo L, Zhao S, Zhang W, Wang Q, Jin Z, Chen X, Sun A, Wu D,Han Y*. Analysis of prognostic factors for survival in 75Chinese patients with peripheral T-cell lymphoma.Leukemia & Lymphoma, 2014;55(4):959-61
30.Han Y, Zhu L, Sun A, Lu X, Hu L, Zhou L, Ren Y, Hu X, Wu X, Wang Z, Ruan C, Wu D. Alterations of hemostatic parameters in the early development of allogeneic hematopoietic stem-cell transplantation related complications.Annal of Hematology, 2011,90(10): 1201-1208.
31.Han Y, Xiao J, Falls E, Zheng XL. A shear-based assay for assessing plasma ADAMTS13 activity and inhibitor in patients with thrombotic thrombocytopenic purpura.Transfusion, 2011, 51(7): 1580–1591.
32.Han Y, Wu D, Sun A, Xie Y, Xu J, Zhou J, Zhu X, Wang Z, Ruan C. Selective embolization of the internal iliac arteries for the treatment of severe hemorrhagic cystitis following hematopoietic SCT.Bone Marrow Transplant. 2008, 41(10):881-886.
33.Han Y, Nurden A, Combrié R, Pasquet JM. Redistribution of glycoprotein Ib within platelets in response to protease-activated receptors 1and 4.J Thromb Haemost, 2003, 1(11):2206-2215.
34.张文娟,韩悦,苏健,白霞,金松,徐明珠,孙爱宁,阮长耿,吴德沛。造血干细胞移植后ADAMTS13缺失的血栓性血小板减少性紫癜一例报告并文献复习。中华血液学杂志,2014,35(1):69-70
35.唐雅琼,韩悦(通讯作者),仇惠英,孙爱宁,吴德沛。重组人凝血因子Ⅶa治疗急性早幼粒细胞白血病合并重度出血八例报告并文献复习。中华血液学杂志,2015,36(2):158-160.
36.胡璐萍,苏建,韩悦等。FRETS-VWF73荧光试验在TTP患者检测中的临床意义。中华血液学杂志,2012,33(9):768-769
37.胡璐萍,韩悦,徐静,叶春梅,周莉莉,任永亚,仇惠英,孙爱宁,吴德沛。脐血移植合并巨细胞病毒感染相关性溶血一例。中华血液学杂志,2011,32 (8) : 761-762
科研项目:
1. TNFα通过骨髓氧化微环境参与移植后血小板减少的调控机制研究,国家自然科学基金(82070143),2021.01-2024.12,课题负责人;
2.氧化微环境HIF-1α通过补体活化在移植相关性血栓性微血管病发生中的调控机制研究,国家自然科学基金(81873432),2019/1/1-2022,课题负责人;
3.氧化微环境HIF-1α通过补体活化在TA-TMA的调控机制研究,江苏省高等学校自然研究重大项目(18KJA320006),2018/9/1-2021,课题负责人;
4.地西他滨治疗造血干细胞移植后持续性血小板减少的疗效及调控机制研究,江苏省社会发展项目,江苏省社会发展面上项目(BE2016665),课题负责人;
5.骨髓微环境ROS作用于巨核重建在HSCT后持续性血小板减少,国家自然科学基金(81670132),2017/1/1-2020,课题负责人;
6.骨髓微环境异常在造血干细胞移植后血小板减少发病的机制研究,江苏省医学重点人才(ZDRCA2016047),2016/1/1-2020,课题负责人;
7.恶性血液病造血干细胞移植后血小板减少治疗研究(人才培养计划),2016/5/1,课题负责人;
8.血栓形成过程中VWF的分子调控及其信号传递机制研究。江苏省自然科学基金项目,BK20131167,2013-2015,课题负责人;
9.血管性血友病因子裂解酶ADAMTS13在血栓形成中的调控机制研究(81270591),国家自然科学基金,2013-2016,课题负责人;
10.移植相关性血栓病变发病机制与诊断治疗的研究.江苏省卫生厅医学重点人才2011-2015,课题负责人;
11.继发性血栓性微血管病变发病机制的研究 江苏省组织部333人才工程(BRA2011218)2011-2013,课题负责人;
12.移植相关性血栓性微血管病变发病机理研究(BK2007508),江苏省自然科学基金项目,2007-2009,课题负责人;
13.慢性特发性血小板减少性紫癜的临床相关性研究 “十一五”国家科技支撑计划 (2007BA120B064),2008-2011,子课题负责人;
14.继发性血栓性血小板减少性紫癫发病机制的研究 江苏省高校自然科学基金(09KJB320014),2009-2011,课题负责人;
15.造血干细胞移植后肝静脉闭塞病的研究 江苏省人事厅六大高峰人才项目,2009-2011,课题负责人;
16.移植相关性血栓性微血管病变的发生机制与治疗研究 江苏省卫生厅医学重点人才(RC2007073),2007-2011,课题负责人;
17.血管性血友病因子裂解蛋白酶在造血干细胞移植后血栓形成过程中的作用研究(SH201024),苏州市国际合作项目. 2010-2011课题负责人;
18.移植相关性血栓病变发病机制与诊断治疗的研究 江苏省卫生厅医学重点人才(RC2011105) 2011-2015,课题负责人Supported by Jiangsu Province’s KeyProvincial Talents Program。
学术奖励:
1.吴德沛、阮长耿、韩悦、武艺、陈苏宁、黄玉辉、王兆钺、戴克胜、傅建新、赵益明。血液系统疾病出凝血异常诊疗新策略的建立及推广应用。2019年国家科学技术进步奖二等奖(2019,排名3/10)
2.韩悦、赵益明、王兆钺、傅建新、戚嘉乾、张翔、唐雅琼、周莉莉、王虹、吴德沛、阮长耿。移植相关性出凝血疾病及其关键机制研究。2018年江苏省科学技术奖一等奖(2018,排名1/11)
3.韩悦、傅建新、赵益明、徐杨、唐雅琼、王兆钺、戚嘉乾、陈佳、吴德沛、阮长耿。血干细胞移植后出凝血异常的发生机制与诊疗新策略研究。2018年高等学校www.优德88.cpm 优秀成果奖-科学技术进步奖一等奖(2018,排名1/10)
4.韩悦、傅建新、陈佳、范祎、赵益明、戚嘉乾、王兆钺、吴德沛、阮长耿。移植相关性出凝血疾病及其关键机制研究。2018年江苏医学科技奖一等奖(2018,排名1/9)
5.韩悦、傅建新、陈佳、范祎、赵益明、戚嘉乾、王兆钺、吴德沛、阮长耿。造血干细胞移植相关出血性疾病的临床及机制研究. 2018年江苏省教育www.优德88.cpm 成果三等奖(2018,排名1/9)
6.韩悦、傅建新、王虹、张剑、范祎、赵益明、唐雅琼、戚嘉乾、张翔、王兆钺、吴德沛、阮长耿。造血干细胞移植相关出血与血栓性疾病的机制及诊疗研究。2018年华夏医学科技三等奖(2018,排名1/12)
7.韩悦、赵益明、吴小津、唐雅琼、傅建新、戚嘉乾、王兆钺、吴德沛、阮长耿。移植相关性出凝血疾病及其关键机制研究。2018年中华医学科技三等奖(2018,排名1/9)
8.韩悦、傅建新、赵益明、唐雅琼、戚嘉乾、王虹、王兆钺、吴德沛、阮长耿。移植相关性出凝血疾病及其关键机制研究。2017年苏州市科学技术进步奖一等奖(2017,排名1/10)
9.吴德沛,陈苏宁,孙爱宁,唐晓文,韩悦,徐杨,吴小津,王荧,张翔。恶性血液肿瘤个体化治疗新策略的建立和推广。2016年江苏省科学技术一等奖(2016年,排
7/10)
10.吴德沛,毛新良,陈苏宁,刘海燕,孙爱宁,唐晓文,韩悦,徐杨,刘跃均,仇惠英,阮长耿。恶性血液肿瘤诊疗关键技术的创新和推广。2016年教育部科技进步一等奖(2016年,排名7/11);
11.王兆钺,韩悦,丽娟等。出血性疾病的诊断、治疗与发病机制研究。江苏省科技进步三等奖,江苏医学科技一等奖,中华医学科技进步三等奖,苏州市科技进步一等奖。(2012)
12.吴德沛,韩悦,吴小津。凝血相关因子检测技术在HSCT早期并发症诊断和治疗应用。江苏省卫生厅新技术引进一等奖。(2013)
13.吴德沛,吴小津,韩悦。基因分型技术在造血干细胞移植后巨细胞病毒感染中的应用。江苏省卫生厅新技术引进一等奖。(2011)
14.吴德沛,韩悦,孙爱宁,王荧,吴小津,马骁,陈广华,符粤文,唐晓文,傅琤琤。移植相关性并发症的研究,教育部科技进步二等奖。(2010)
15.吴德沛,孙爱宁,韩悦,王荧,马骁,吴小津,陈广华,唐晓文,傅琤琤。异基因造血干细胞移植方式与部分并发症的基础研究与临床应用,江苏省科技进步三等奖,苏州市科技进步一等奖。(2010)
16.吴德沛,韩悦,朱霞明。造血干细胞移植术后出血性膀胱炎的诊治新方法。江苏省卫生厅新技术引进一等奖。(2009)
17.韩悦,白霞,王兆钺,戴兰,沈文红,阮长耿.流式细胞术在血栓与出血研究中的应用。江苏省科技进步三等奖(2008),苏州市科技进步二等奖。(2006).
18.韩悦,吴德沛,孙爱宁,张威,白霞,王兆钺,阮长耿。凝血酶受体活化与血小板信号传导机制研究。苏州市科技进步二等奖。(2008).
授权发明专利:
1.吴徳沛,韩悦,梁建英,朱明清,阮长耿.地西他滨在治疗造血干细胞移植后血小板减少中的应用,专利授权日2016.3.2,ZL 201410186295.6